In addition, cysteine-rich intestinal protein 1 (CRIP1) was established as a novel target for clinical drug resistance of colorectal cancer, which could interact with Fas and stimulate its ubiquitination and degradation [17]. This evidence concerns the gene CRIP1 and colorectal cancer.